India, Feb. 8 -- Regeneron Pharmaceuticals Inc. (REGN) announced positive three-year (156-week) results for EYLEA HD (aflibercept) Injection 8 mg in patients with wet age-related macular degeneration or wAMD from an extension study of the Phase 3 PULSAR trial.
Similar to the three-year results for the pivotal PHOTON trial in diabetic macular edema (DME), the longer-term wAMD data demonstrated the vast majority of EYLEA HD patients who entered the extension study sustained the visual gains and anatomic improvements achieved by the end of the second year, while also achieving substantially longer treatment intervals.
In addition, patients who switched from EYLEA (aflibercept) Injection 2 mg to EYLEA HD at the beginning of the third year wer...